Cardiff Oncology, Inc.

NASDAQ:CRDF

Biotechnology

Healthcare
$0.84 +2.12%

+$0.03 today

Market cap
$65.27M
Beta
1.38
P/E (TTM)
-1.8
EPS (TTM)
-$0.65
52W Low $1.16High $4.56

Volume 0.86M

Average 1.05M

CRDF Account Payables

Amounts the company owes suppliers for goods and services received.

Cardiff Oncology, Inc.NASDAQ: CRDF

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables rises 51.0% from a year ago

Account payables stood at $5.48M at the end of Q1 FY2026, up 51.0% from a year earlier and down 32.2% from the prior quarter. Over 3 fiscal years it compounded at +60.5% a year.

Context

  • Account payables amounted to 11.1% of total assets at the end of Q1 FY2026, up 6.9 pp from a year earlier.
  • Account payables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether account payables keeps rising in the next quarterly balance sheet after a +51.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.48M-32.2% QoQ
Last fiscal yearDec 2025
$8.09M+67.7% YoY
Year agoMar 2025
$3.63M+51.0% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+51.0%——
1 year+67.7%——
3-year CAGR+60.5%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
8.09M USD
Year-over-year change
+67.7%
4-year CAGR
+54.0%

Account Payables vs competitors

How CRDF compares with its peers on the latest reported figures

  • Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +51.0% is the 4th highest of 9, against a peer median of -31.7%.
  • Account payables amounts to 11.1% of total assets for CRDF, versus a peer median of 1.9%.
CRDF Competitors
Account Payables for CRDF and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IPHAInnate Pharma S.A.Dec 2025€15.04M EUR+89.8%+3.3%24.0%
FBRXForte Biosciences, Inc.Mar 2026$13.08M USD+160.5%+105.4%19.5%
MISTMilestone Pharmaceuticals Inc.Mar 2026$10.02M USD+320.4%+35.6%5.2%
CRDFCardiff Oncology, Inc.Mar 2026$5.48M USD+51.0%+60.5%11.1%
MOLNMolecular Partners AGMar 2026CHF 1.92M CHF-19.9%-2.0%2.2%
RANIRani Therapeutics Holdings, Inc.Mar 2026$858K USD-43.6%-40.4%1.7%
PEPGPepGen Inc.Mar 2026$622K USD-77.0%-15.5%0.4%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$435K USD-89.3%+0.6%0.3%
ELTXElicio Therapeutics, Inc.Mar 2026$272K USD-93.3%-37.9%1.2%
Peer median (excluding CRDF) —-31.7%-0.7%1.9%

Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents11.94M16.35M21.66M51.47M17.47M
Short-term Investments128.88M88.92M53.17M40.28M40.83M
Net Receivables535K771K288K773K182K
Inventory00000
Other Current Assets05.25M2.3M2.54M1.64M
Total Current Assets146.13M111.28M77.41M95.05M60.13M
Property, Plant & Equipment (Net)3.18M3.52M2.95M2.07M1.21M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets239K1.39M1.28M69K549K
Total Non-current Assets3.42M4.91M4.23M2.14M1.76M
Total Assets149.54M116.19M81.64M97.19M61.88M
Account Payables1.44M1.96M1.97M4.82M8.09M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.48M1.85M5.05M2.75M2.43M
Total Current Liabilities6.56M7.81M10.44M13.43M16.39M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities2.57M2.04M1.46M813K102K
Total Liabilities9.13M9.85M11.9M14.24M16.5M
Common Stock4K4K4K7K7K
Retained Earnings(259.81M)(298.1M)(339.54M)(384.18M)(430.03M)
Accumulated OCI(142K)(395K)(67K)34K50K
Other Stockholders Equity(139K)0000
Minority Interest00000
Total Equity140.42M106.34M69.74M82.95M45.39M
Total Debt3.12M2.72M2.15M1.52M832K
Net Debt(8.82M)(13.63M)(19.51M)(49.95M)(16.64M)

Cardiff Oncology, Inc.

NASDAQ:CRDF

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.